The cell-free fetal DNA testing market is to capture a CAGR of 10.9% during the forecast period. The market is projected to be valued at USD 1,466.3 million in 2023 and is likely to be worth USD 4,124.7 million by 2033.
The adoption of cell-free fetal DNA testing is likely to rise due to an extension of prenatal testing in a safe and non-invasive method during the forecast period. However, prenatal tests are used to find any irregularities in a fetus with screening procedures.
The two predominant prenatal tests are chorionic villus sampling (CVS) and amniocentesis. These both are invasive and could possess harm to the developing fetus. In some cases, it can cause miscarriage. Hence, to detect such problems, the demand for cell-free fetal DNA testing is likely to rise in recent years.
It is possible to do cell-free fetal DNA testing to determine the health of the fetus if the mother has been exposed to teratogens like alcohol, lead, or UV radiation. Growing public awareness of fetal anomalies is projected to be one of the factors driving high revenue share in the cell-free DNA testing market.
| Report Attributes | Details |
|---|---|
| Cell-free Fetal DNA Testing Market Value (2023) | USD 1,466.3 million |
| Cell-free Fetal DNA Testing Market Anticipated Value (2033) | USD 4,124.7 million |
| Cell-free Fetal DNA Testing Market Projected Growth Rate (2023 to 2033) | 10.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
A Significant Shift in Diagnosis
Amniocentesis and chorionic villus sampling prenatal tests are possible within 14-20 weeks and 10-13 weeks of pregnancy respectively. However, cell-free fetal DNA testing is used to detect aneuploidy syndromes and fetal Down syndrome and signals a vital shift in diagnostic practice and prenatal screening. These all factors are flourishing in the market size during the forecast period.
Growing Awareness
The growth of the global cell-free fetal DNA testing market is increasing awareness and the requirement for safe or low-risk obstetric procedures for prenatal testing. Moreover, the technology is used in cell-free DNA analysis and its application to prenatal screening for aneuploidy is rapidly changing in recent years.
Technical Advancements
As technology progresses, improved innovative testing techniques are projected to hit the market and increase competition, which may put pressure on leading players in the cell-free fetal DNA testing industry. It is preferred over karyotyping due to its accurate results and growing demand from end-user segments.
Effective Results
The growth of the cell-free fetal DNA testing market is primarily attributed to accurate and effective results for aneuploidy screening during the forecast period. To detect specific changes, chromosomal abnormalities, and other several conditions of an unborn baby raising the demand for cell-free fetal DNA testing for better results in recent years.
The high cost of cell-free fetal DNA testing is one of the main reasons limiting the growth of the global market for these tests. Due to patients' limited disposable means, which are unable to adopt cell-free fetal DNA testing, the market's size has recently been constrained.
Cell-free fetal DNA testing is not always accurate in the case of twins, and the market expansion for these tests is expected to be constrained by their high costs, a shortage of qualified physicians, the absence of insurance coverage for these tests, and their poor reimbursement.
Principal Consultant
| Region | North America |
|---|---|
| Market Share % (2022) | 36.5% |
The global cell-free fetal DNA testing market is expected to register a healthy CAGR for the forecast period. North America dominates the cell-free fetal DNA testing market as it held more than 36.5% of the share in 2022.
Due to the rising high occurrence of several diseases, rising number of aneuploidies, advancement in the field of aneuploidies, and developed healthcare infrastructure. The market in North America is rising with the adoption of cell-free fetal DNA testing in recent years.
| Region | Europe |
|---|---|
| Market Share % (2022) | 32.2% |
The Europe region is followed by North America to hold huge potential for growth in the global cell-free fetal DNA testing market as it held 32.2% of the share in 2022.
The demand for cell-free fetal DNA testing has increased in recent years due to its quick and accurate results, without any risk to developing fetuses. The United Kingdom is a prominent country to lead the market in the region due to several abnormalities and safe detection during the forecast period.
The Asia Pacific cell-free fetal DNA testing industry is projected to expand at a stellar pace through 2033. FMI has projected that India’s market is estimated to witness a 12.4% CAGR, whereas China’s market is estimated to exhibit an 11.6% CAGR. These high-growth countries are pulling up the overall market growth rate.
Genetic diseases impact the fetuses in the mother’s womb. Early detection and diagnosis of these diseases help measure the total risk of these diseases and the chances of their recurrence.
Also, parents with a family history or an existing child with a genetic disease bear a high risk of having such a child. All these factors and high fertility rates indicate how important cell-free fetal DNA testing is among expecting parents.
Technological advances and upgradation in the medical infrastructure in the economies of Asia are fueling market expansion further. Surging awareness about the necessity of prenatal testing is emerging as another key propeller for cell-free fetal DNA testing.
The rapidly spreading diagnostic sector in the region is underpinned by robust adoption and surging technological advancements. The booming diagnostic sector is projected to have a positive effect on the application of cell-free fetal DNA testing.
The growth of cell-free fetal DNA testing is running parallel to the increasing fertility rates and genetic diseases among infants. Furthermore, the advancing healthcare scene is expected to have a compounding effect on the growth of cell-free fetal DNA testing in developed and developing countries alike.
The high birth rate, large population, and consanguineous marriage tradition in certain Indian communities are fueling the rate of genetic disorders in India. As a result, the surging prevalence of genetic disorders in infants is catalyzing the demand for cell-free fetal DNA testing.
A couple of factors, including the surging number of pregnant females using prenatal screening and rising mandatory policies for screening tests, are pushing the adoption of cell-free fetal DNA testing.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market based on test type is categorized into abnormal chromosome number detection, gender testing, and paternally inherited disorder detection. Among these, the abnormal chromosome number detection type dominates the market during the forecast period.
This segment type locates the additional chromosome in a pregnant woman's blood, as well as the missing chromosome. Furthermore, aberrant chromosome number identification has recently been used to test for Down syndrome and other disorders.
New investors are entering the market as a result of technological advancements and increased income potential. Cell-free fetal DNA testing is becoming more popular as the demand for comprehensive patient care rises. For instance,
The market is populated with large as well as medium-sized players vying for a great market share. Manufacturers are taking solid steps like research and development and making efforts in sourcing the latest technology.
The key businesses are developing a variety of remedies to meet patients' expectations for a sickness cure. These players are gaining the lion's share while using different marketing strategies to increase sales. Collaborations, mergers, and acquisitions are a few of these tactics.
Vendors are also strengthening their distribution network in different countries. Moreover, firms are taking strategic initiatives to invigorate their market position.
Recent Developments in the Cell-free Fetal DNA Testing
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 10.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
Test Types; Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; The Middle East and Africa |
| Key Countries Profiled | The United States, Canada, Brazil, Argentina, Germany, The United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC, South Africa |
| Key Companies Profiled | Sequenom Laboratories; Illumina, Inc.; Ariosa Diagnostics; Arup Laboratories; The Fetal Medicine Centre; Apollo Path labs |
| Customization | Available Upon Request |
In the current year 2023, the overall market size could be around USD 1,466.3 million.
Until 2033, the overall demand for cell-free fetal DNA testing services could progress at 10.9% CAGR.
The regional market players together contributed for about 36.5% of the global market revenue.
Adoption of cell-free fetal DNA testing services in Europe held almost 32.2% market share in 2022.
The abnormal chromosome number detection segment remains in higher demand.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type 5.1. Detection of Abnormal Chromosome Number 5.2. Gender Testing 5.3. Paternally Inherited Disorders 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 6.1. North America 6.2. Latin America 6.3. Western Europe 6.4. Eastern Europe 6.5. South Asia and Pacific 6.6. East Asia 6.7. Middle East and Africa 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Sequenom Laboratories 16.2. Illumina, Inc. 16.3. Ariosa Diagnostics 16.4. Arup Laboratories 16.5. The Fetal Medicine Centre 16.6. Apollo Path labs 16.7. Trovagene, Inc 16.8. Roche Holdings AG 16.9. Berry Genomics Co. Ltd 16.10. Premaitha Health 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Cell-free Fetal DNA Testing Market
